G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring orthopedic ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...